Verona Pharma PLC American Depositary Share Closes at $23.69, Down 0.96% from Previous Day
January 19, 2023
Trending News ☀️
Verona Pharma Intrinsic Value – Verona Pharma ($NASDAQ:VRNA) PLC American Depositary Share (ADR) closed at $23.69 on Tuesday, representing a decrease of 0.96% from the previous day’s closing price. This news is significant for investors who are monitoring the stock as it presents an opportunity to assess the current performance of the company. Verona Pharma PLC is a specialty pharmaceutical company focused on the development and commercialization of treatments for respiratory diseases.
Verona Pharma has established a strong pipeline of potential drugs and therapeutic agents that could help to treat respiratory conditions. While the stock price was down 0.96% for the day, investors should keep an eye on the company’s progress as it continues to develop its drugs and move them through the clinical trial process. Verona Pharma PLC ADR is an interesting investment opportunity for those looking to capitalize on the potential of this innovative pharmaceutical company.
Share Price
At the time of writing, media exposure of the company was mainly positive. The decrease in the share price was likely due to a lack of any major news or developments from the company. Investors may have been disappointed by the lack of progress from VERONA in terms of new products or services that could have boosted their share price. The company is still in the early stages of development and is yet to make any major announcements.
In the near term, traders and investors should keep an eye on any news coming out of Verona Pharma for potential trading opportunities. Overall, the stock has been relatively stable over the past few weeks and investors should take this as a sign that VERONA is well-positioned for growth in the coming months as it continues to develop new products and services. Investors should also keep an eye on its share price movements to gauge any potential changes in sentiment or outlook regarding the company. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Verona Pharma. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -81.51 | -145.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Verona Pharma. More…
| Operations | Investing | Financing |
| -69.45 | -0.03 | 137.3 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Verona Pharma. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 274.87 | 37.39 | 3.15 |
Key Ratios Snapshot
Some of the financial key ratios for Verona Pharma are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -138.1% |
| FCF Margin | ROE | ROA |
| -83.2% | -29.1% | -18.5% |
VI Analysis – Verona Pharma Intrinsic Value Calculator
Verona Pharma is a pharmaceutical company that has strong fundamentals and long term potential. The VI app has made it simpler to analyze its financials, and the fair value of the company’s stocks is around $7.7 according to the VI Line. Currently, the stocks are trading at $22.7, which is an overvaluation of 194% compared to what is considered as fair value. This suggests a potential opportunity for investors who are looking to buy the stocks at a discounted price. The company’s fundamentals are a good indication of its long-term prospects, the current overvaluation should not be taken as an indication of future growth. Investors should carefully evaluate the company’s financials and future outlook before making any investment decisions. More…
VI Peers
Some of its competitors are Karuna Therapeutics Inc, Cardiff Oncology Inc, Reviva Pharmaceuticals Holdings Inc.
– Karuna Therapeutics Inc ($NASDAQ:KRTX)
Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing and commercializing novel treatments for patients with psychiatric and neurological disorders. The company’s lead product candidate, KarXT, is a novel, oral, small molecule that is being developed for the treatment of schizophrenia. KarXT has the potential to improve cognitive function, negative symptoms, and overall functioning in patients with schizophrenia. The company has completed a Phase II clinical trial of KarXT in patients with schizophrenia and is currently enrolling patients in a Phase III clinical trial.
– Cardiff Oncology Inc ($NASDAQ:CRDF)
Cardiff Oncology is a clinical-stage biotechnology company focused on the development of novel cancer therapies. The company’s lead product candidate, CZC24832, is a first-in-class, orally-available small molecule inhibitor of the PI3K/mTOR pathway. The PI3K/mTOR pathway is a key driver of cancer cell growth and proliferation. CZC24832 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors.
Cardiff Oncology has a market cap of $59.42 million and a return on equity of -21.11%. The company’s lead product candidate, CZC24832, is a first-in-class, orally-available small molecule inhibitor of the PI3K/mTOR pathway. The PI3K/mTOR pathway is a key driver of cancer cell growth and proliferation. CZC24832 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors.
– Reviva Pharmaceuticals Holdings Inc ($NASDAQ:RVPH)
Reviva Pharmaceuticals Holdings Inc is a pharmaceutical company with a market cap of 107.33M as of 2022 and a Return on Equity of -63.24%. The company’s main focus is on the development and commercialization of drugs for the treatment of central nervous system disorders.
Summary
Verona Pharma PLC (VRNA) has been trading at $23.69, a decrease of 0.96% compared to the previous day. The overall public opinion on VRNA appears to be positive, yet the stock price has fallen. Investors should weigh the potential risks and rewards that come with investing in VRNA, as well as consider the current market conditions, before committing capital to the company.
Research should include analyzing the company’s financials, news, and industry trends. If the stock appears undervalued and there is strong potential for growth, then it might be a wise investment.
